Henlius Reports Revenue Rise For First Quarter Of 2024
The Company’s Core Products Showed Growth Compared To Last Year
The Chinese biotech reported increased growth in its revenue fuelled by its portfolio of biologic drugs and biosimilars, with further plans for approvals around the world.
